<DOC>
	<DOCNO>NCT01978743</DOCNO>
	<brief_summary>In study investigator use multi-modal imaging approach MRS fMRI comprehensively assess biological change brain associate EFV-based regimen ( EFV/FTC/TDF ) , specifically alteration brain circuitry , function local neurochemistry , correlation neuropsychological function . In cohort HIV-infected patient clinically stable commonly use regimen EFV/emtricitabine ( FTC ) /truvada ( TDF ) Atripla , investigator propose replace EFV component integrase inhibitor , Raltegravir ( RAL ) , give RAL FTC/TDF evaluate EFV-related neural alteration . This multidisciplinary study lead Dr. Nina Lin , collaboration research team Dr. Alexander Lin , Director Center Clinical Spectroscopy , Dr. Emily Stern , Director Functional Neuroimaging Laboratory , member Brigham Women 's Department Radiology Harvard Medical School , well Dr. Jane Epstein , researcher Dr. Stern 's research group . Dr. Epstein staff psychiatrist Brigham Women 's hospital extensive experience expertise research abnormality affective motivational processing context neuropsychiatric disorder . Investigators utilize establish clinical research platform Infectious Disease outpatient clinical practice Brigham Women 's Hospital , currently many ongoing HIV-related study large panel HIV-infected patient motivate involve clinically relevant research . Investigators propose use advance neuroimaging measure biologically change brain associated long-term EFV use follow specific aim : 1 . Determine change neurometabolites measure MRS brain associate long-term EFV use 2 . Assess alteration neural activity correlate affective symptom associate EFV v RAL use use fMRI , association change neurometabolites assess MRS , change cognition assess Trail Making Digit Substitution Tests . 3 . Determine change emotion , cognition sleep quality switch EFV RAL , correlate subject treatment preference . This clinical study extend current understanding EFV neurotoxicity define nature biological change . Further elucidation neurobiological underpinnings EFV-induced CNS toxicity clinical relevance improve quality life drug adherence HIV-infected patient ART , especially among old patient baseline neuropsychiatric disorder , baseline vulnerable neurocognitive decline long-term HIV infection .</brief_summary>
	<brief_title>Advanced Neuroimaging Evaluation Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch Raltegravir-based Regimen</brief_title>
	<detailed_description />
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Neurocognitive Disorders</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Chronic HIVinfected individual suppressive regimen EFV/FTC/TDF , least 6 month 2 . Undetectable HIV1 RNA virus load least 6 month 3 . No coinfections active hepatitis B C 4 . Presence least moderate symptom 2 3 subcores DASS 5 . No known active HIVrelated nonHIV related CNS infection 6 . Estimated glomerular filtration rate ( EGFR ) &gt; 60 ml/min 7 . Consent switch EVG/COBI/FTC/TDF 8 . Ages 18 65 1 . History CNS opportunistic infection active CNS infection 2 . History severe psychiatric disorder ( exclude depression anxiety ) 3 . History chronic neurological disorder , epilepsy multiple sclerosis 4 . History current significant substance abuse dependence and/or heavy alcohol use ( &gt; 12 oz/wk ) 5 . Any woman may pregnant ( positive urine pregnancy test unprotected sex 2 week prior scan ) know pregnant 6 . Contraindications undergo fMRI , include metallic implant , claustrophobia , medical condition medication significantly affect cerebral blood flow function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-associated neurocognitive disorder</keyword>
	<keyword>neurotoxicity</keyword>
</DOC>